CA2373938A1 - Compositions and methods for treating cell proliferation disorders - Google Patents

Compositions and methods for treating cell proliferation disorders Download PDF

Info

Publication number
CA2373938A1
CA2373938A1 CA002373938A CA2373938A CA2373938A1 CA 2373938 A1 CA2373938 A1 CA 2373938A1 CA 002373938 A CA002373938 A CA 002373938A CA 2373938 A CA2373938 A CA 2373938A CA 2373938 A1 CA2373938 A1 CA 2373938A1
Authority
CA
Canada
Prior art keywords
cells
tumor
antagonist
human
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002373938A
Other languages
English (en)
French (fr)
Inventor
Herve Fridman
Eric Tartour
Jacques Banchereau
Francois Fossiez
Serge J. E. Lebecque
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2373938A1 publication Critical patent/CA2373938A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002373938A 1999-05-17 2000-03-27 Compositions and methods for treating cell proliferation disorders Abandoned CA2373938A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99401191.4 1999-05-17
EP99401191A EP1053751A1 (en) 1999-05-17 1999-05-17 Compositions and methods for treating cell proliferation disorders
PCT/US2000/008081 WO2000069463A1 (en) 1999-05-17 2000-03-27 Compositions and methods for treating cell proliferation disorders

Publications (1)

Publication Number Publication Date
CA2373938A1 true CA2373938A1 (en) 2000-11-23

Family

ID=8241974

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002373938A Abandoned CA2373938A1 (en) 1999-05-17 2000-03-27 Compositions and methods for treating cell proliferation disorders

Country Status (6)

Country Link
EP (2) EP1053751A1 (enExample)
JP (1) JP2004500325A (enExample)
AU (1) AU4033900A (enExample)
CA (1) CA2373938A1 (enExample)
MX (1) MXPA01011923A (enExample)
WO (1) WO2000069463A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003281200A1 (en) * 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
EP1641822B1 (en) 2003-07-08 2013-05-15 Genentech, Inc. Il-17 a/f heterologous polypeptides and therapeutic uses thereof
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
JP5068270B2 (ja) * 2006-01-31 2012-11-07 ノバルティス アーゲー 癌を処置するためのｉｌ−１７アンタゴニスト抗体
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
EP2569335B1 (en) * 2010-05-14 2018-08-22 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
CN103384682B (zh) 2011-01-14 2017-04-12 Ucb医药有限公司 结合il‑17a和il‑17f的抗体分子
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
KR102617833B1 (ko) 2016-05-06 2023-12-27 엑시큐어 오퍼레이팅 컴퍼니 인터류킨 17 수용체 mRNA의 특이적 녹다운을 위한 안티센스 올리고뉴클레오티드 (ASO)를 제시하는 리포좀성 구형 핵산 (SNA) 구축물
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
EP4087858A1 (en) * 2020-01-10 2022-11-16 Carogen Corporation Compositions and methods of use of oncolytic virus like vesicles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1591529A3 (en) * 1995-07-19 2005-11-09 Genetics Institute, LLC Human CLTA-8 and uses of CTLA-8-related proteins
AU9482498A (en) * 1997-09-17 1999-04-05 Human Genome Sciences, Inc. Interleukin-17 receptor-like protein
DE29820466U1 (de) * 1998-11-16 1999-04-08 Reutter, Werner, Prof. Dr.med., 14195 Berlin Rekombinante Glycoproteine und sie enthaltende Arzneimittel

Also Published As

Publication number Publication date
WO2000069463A1 (en) 2000-11-23
EP1251872A1 (en) 2002-10-30
JP2004500325A (ja) 2004-01-08
MXPA01011923A (es) 2003-10-15
AU4033900A (en) 2000-12-05
EP1053751A1 (en) 2000-11-22

Similar Documents

Publication Publication Date Title
EP1053751A1 (en) Compositions and methods for treating cell proliferation disorders
Klein et al. Survival and proliferation factors of normal and malignant plasma cells
Blam et al. Integrating anti–tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives
Tartour et al. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice
AU740478B2 (en) Use of macrophage migration inhibitory factor antagonists for anti-cancer therapy
US20110123603A1 (en) Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
US20080167264A1 (en) Materials and methods to inhibit hodgkin and reed sternberg cell growth
EP3119806B1 (en) Il-21 antibodies
HU221343B1 (en) Use of anti-vegf antibodies for the treatment of cancer
JP2007186523A (ja) 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
CN107530419A (zh) 治疗疾病的组合疗法
TW200803895A (en) Method of using IL6 antagonists with proteasome inhibitors
EA018717B1 (ru) Антитело или фрагмент антитела, которое связывается с белком ron человека, и его применение
JP2014508117A (ja) 癌および癌細胞遊走の予防および治療のための抗ｃｃｌ２５および抗ｃｃｒ９抗体
KR102674516B1 (ko) Il-33 안타고니스트를 포함하는 자궁내막증 치료제
EP2866830A1 (en) Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation
US20160130350A1 (en) Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation
US9233120B2 (en) Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
CN116348488A (zh) 犬白介素-31受体α的犬源化大鼠抗体
CA2546017A1 (en) Use of notch pathway interfering agents for treatment of plasma cell disorders
WO2001005821A2 (en) Viral il-10 for the inhibition of angiogenesis, tumorigenesis and metastasis
EP2240517B1 (en) Fdf03 antibodies and uses thereof
EP3277718B1 (en) Dosage regimen for anti-mif antibodies
WO2018206496A1 (en) Inhibitors of il-38 for use in treating and/or preventing cancer in a subject
WO2000044408A2 (en) Method of treating demyelinating inflammatory disease using ccr1 antagonists

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued